Eligibility for Statin Treatment in Korean Subjects with Reduced Renal Function: An Observational Study

min/1.73 m 2 ; stage 2, eGFR 60 to 89 mL/min/1.73 m 2 ; and stages 3 to 5, eGFR <60 mL/min/1.73 m 2 . Statin eligibility in these groups was determined using the ATP III and ACC/AHA guidelines, and the risk for 10-year atherosclerotic cardiovascular disease (ASCVD) was calculated using the Framingham Risk Score (FRS) and Pooled Cohort Equation (PCE). Results: There were 3,546 (18.9%) and 4,048 (21.5%) statin-eligible subjects according to ATP III and ACC/AHA guidelines, re- spectively. The proportion of statin-eligible subjects increased as renal function deteriorated. Statin eligibility by the ACC/AHA guidelines showed better agreement with the Kidney Disease Improving Global Outcomes (KDIGO) recommendations compared to the ATP III guidelines in subjects with stage 3 to 5 chronic kidney disease (CKD) (κ value, 0.689 vs. 0.531). When the 10-year AS- CVD risk was assessed using the FRS and PCE, the mean risk calculated by both equations significantly increased as renal function declined. Conclusion: The proportion of statin-eligible subjects significantly increased according to worsening renal function in this Korean cohort. ACC/AHA guideline showed better agreement for statin eligibility with that recommended by KDIGO guideline compared to ATP III in subjects with CKD.